Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany

[1]  A. Meisel,et al.  Mental health in myasthenia gravis patients and its impact on caregiver burden , 2022, Scientific Reports.

[2]  Jacqueline A Palace,et al.  Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders , 2022, The Lancet Neurology.

[3]  Derek G Cook,et al.  Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data , 2021, PloS one.

[4]  Jonas Jacobi,et al.  Burden of disease in myasthenia gravis: taking the patient’s perspective , 2021, Journal of Neurology.

[5]  M. Leite,et al.  Comorbidities in older patients with myasthenia gravis — Comparison between early‐ and late‐onset disease , 2021, Acta neurologica Scandinavica.

[6]  F. Piehl,et al.  Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort , 2021, Neurology.

[7]  A. Kostera-Pruszczyk,et al.  Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study , 2021, Neuroepidemiology.

[8]  T. Wilke,et al.  Hospitalized with stroke at the weekend: Higher cost and risk of early death? , 2021, International journal of stroke : official journal of the International Stroke Society.

[9]  P. Urban,et al.  A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus , 2021, Journal of central nervous system disease.

[10]  Jacqueline Palace,et al.  International Consensus Guidance for Management of Myasthenia Gravis , 2020, Neurology.

[11]  V. Bril,et al.  Prospective study of stress, depression and personality in myasthenia gravis relapses , 2020, BMC Neurology.

[12]  A. Punga,et al.  Epidemiology of Myasthenia Gravis in Sweden 2006–2016 , 2020, Brain and behavior.

[13]  F. Griesinger,et al.  Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis , 2020, BMC Cancer.

[14]  A. López de Munain,et al.  Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. , 2020, Neurology.

[15]  J. Howard,et al.  Clinical outcome measures following plasma exchange for MG exacerbation , 2019, Annals of clinical and translational neurology.

[16]  A. Yang,et al.  Risk of Depressive Disorders Following Myasthenia Gravis: A Nationwide Population-Based Retrospective Cohort Study , 2019, Front. Psychiatry.

[17]  G. L’italien,et al.  Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life , 2019, Journal of clinical neuromuscular disease.

[18]  A. Vincent,et al.  A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England , 2019, Neuroepidemiology.

[19]  N. Gilhus,et al.  Myasthenia gravis , 2019, Nature Reviews Disease Primers.

[20]  T. Ruck,et al.  Understanding the burden of refractory myasthenia gravis , 2019, Therapeutic advances in neurological disorders.

[21]  N. Engel-Nitz,et al.  Burden of illness in patients with treatment refractory myasthenia gravis , 2018, Muscle & nerve.

[22]  M. Fulová,et al.  Epidemiology of Myasthenia Gravis in Slovakia in the Years 1977–2015 , 2018, Neuroepidemiology.

[23]  L. Jacobson,et al.  A nationwide epidemiological study of myasthenia gravis in Latvia , 2018, European journal of neurology.

[24]  R. Mantegazza,et al.  When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies , 2018, Therapeutic advances in neurological disorders.

[25]  M. Schroeter,et al.  Myasthenia Gravis – Exacerbation and Crisis , 2018, Neurology International Open.

[26]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[27]  S. Borghs,et al.  Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs , 2017, German medical science : GMS e-journal.

[28]  E. Santos,et al.  Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases , 2016, Muscle & nerve.

[29]  P. Bourque,et al.  Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study , 2016, PloS one.

[30]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[31]  Jacqueline A Palace,et al.  Myasthenia gravis: a clinical-immunological update , 2015, Journal of Neurology.

[32]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[33]  P. Mccombe,et al.  Clinical features and impact of myasthenia gravis disease in Australian patients , 2015, Journal of Clinical Neuroscience.

[34]  F. Piehl,et al.  The autoimmune spectrum of myasthenia gravis: a Swedish population‐based study , 2015, Journal of internal medicine.

[35]  A. Nair,et al.  Ocular myasthenia gravis: A review , 2014, Indian journal of ophthalmology.

[36]  A. Engeland,et al.  Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries , 2014, Acta neurologica Scandinavica. Supplementum.

[37]  J. Sieb.  Myasthenia gravis: an update for the clinician , 2014, Clinical and experimental immunology.

[38]  D. Godoy,et al.  The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit. , 2013, Arquivos de neuro-psiquiatria.

[39]  Nils Erik Gilhus,et al.  Myasthenia Gravis: A Review of Available Treatment Approaches , 2011, Autoimmune diseases.

[40]  J. Levine,et al.  Myasthenic Crisis , 2011, The Neurohospitalist.

[41]  H. Kim,et al.  Prediction of Mortality in Patients Undergoing Maintenance Hemodialysis by Charlson Comorbidity Index Using ICD-10 Database , 2010, Nephron Clinical Practice.